MétaCan
Menu
Back to cohort
Record W2306625559 · doi:10.14288/1.0102579

The impact of international trade agreements on health : patent system harmonization and medicines in Mexico

2012· article· en· W2306625559 on OpenAlexaboutno aff
Benjamin Charles Warren

Bibliographic record

VenuecIRcle (University of British Columbia) · 2012
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicPharmaceutical Economics and Policy
Canadian institutionsnot available
Fundersnot available
KeywordsInternational tradeHarmonizationBusinessInternational economicsEconomics

Abstract

fetched live from OpenAlex

Patent system harmonization obligations found within international trade agreements have been subject to intense scrutiny over the past two decades due to the potential negative implications for public health in developing countries. In 1994, NAFTA became the first trade agreement to include patent system harmonization obligations. Mexico as a signatory to NAFTA was the first developing country to adopt the patent system of developed countries via patent system harmonization. This makes Mexico a particularly relevant case study on the subject. The central research question addressed in this dissertation is: Does NAFTA patent system harmonization promote access to medicines in Mexico, while incentivizing pharmaceutical R&D? This dissertation undertakes a comparative legal analysis, a scoping study, and qualitative stakeholder analysis to address the central research question. Evidence is provided that compulsory licensing as a safeguard is inadequate as a downstream measure in the promotion of access. A key finding is that international trade agreements should be drafted with optimal pharmaceutical patent protection standards in mind. Further, patent system harmonization results in a net health benefit that can be maximized through the provision of feedback evidence to decision-makers in order to develop responsive laws and policy. This dissertation proposes that: if we reform the granting of patent terms from a fixed twenty year life period to a flexible and adjustable term determined through an assessment of health and economic conditions that exist during any given time period, we will improve both global equity in access to medicines and reduce economic inefficiencies in our current model for pharmaceutical R&D, while maintaining adequate incentives to conduct pharmaceutical R&D. The proposed reform is akin to the use of interest rates as an economic growth and stabilization tool in monetary policy. It would require government patent offices to analyze global conditions in pharmaceutical access and R&D, and accordingly adjust the number of years of patent protection awarded. This novel contribution to the academic literature informs Canadian, Mexican, and developing country decision makers on how to design appropriate policy for the benefit of public health.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.045
Threshold uncertainty score0.104

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0060.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0020.003
Science and technology studies0.0030.004
Scholarly communication0.0060.004
Open science0.0010.005
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.241
Teacher spread0.197 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venuecIRcle (University of British Columbia)Same topicPharmaceutical Economics and PolicyFrench-language works237,207